MedPage Today on MSN

Jail-based HCV testing, treatment may deliver substantial community returns

Approach focuses interventions at the nexus of injection drug use, HCV, and incarceration ...
AOL

Atea Pharma (AVIR) Earnings Call Transcript

Image source: The Motley Fool. Atea Pharmaceuticals (NASDAQ:AVIR) advanced key clinical programs, completing North American Phase III patient enrollment for HCV and projecting global top-line results ...
Seeking Alpha

Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus

Enrollment Completed in C-BEYOND Phase 3 Trial with More Than 880 HCV Treatment-Naïve Patients in US and Canada C-BEYOND Topline Results Expected Mid-2026 C-FORWARD Phase 3 Trial, Conducted Outside ...

Atea anticipates top line phase III HCV results midyear 2026 while advancing HEV program

Q4 2025 Management View Jean-Pierre Sommadossi, Founder, Chairman, CEO & President, reported substantial clinical progress, highlighting advancement in the global Phase III program evaluating ...